Search research articles
Contact Us
Filters
Showing results (261-270 of 290) with videos related to
Page
of 29
Sort By:
American Journal of Cancer Research
|
February 13, 2023
Clinical features of patients with <i>MTAP</i>-deleted bladder cancer
Andre L De Souza, Anthony E Mega, John Douglass, et al.
Blood Advances
|
September 22, 2021
Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma
Adam J Olszewski, Anna D Chorzalska, Max Petersen, et al.
British Journal of Haematology
|
November 10, 2022
Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles
Diana O Treaba, Dennis M Bonal, Anna Chorzalska, et al.
Breast Cancer Research and Treatment
|
June 4, 2021
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
M L Lopresti, J J Bian, B J Sakr, et al.
Blood
|
July 29, 2025
HiJAKing the Hematopoietic System: A Low-Frequency JAK2V617F Clone Drives Myeloproliferative Neoplasm Pathology
Dennis M Bonal, Alissa Oakes, Anna Chorzalska, et al.
Blood Advances
|
June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
Narendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Nature Medicine
|
December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Lihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Journal of Hematology & Oncology
|
May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Blood
|
September 15, 2018
Bone marrow-specific loss of
Anna Chorzalska, John Morgan, Nagib Ahsan, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 290) with videos related to
Sort By:
Page
of 29
American Journal of Cancer Research
|
February 13, 2023
Clinical features of patients with <i>MTAP</i>-deleted bladder cancer
Andre L De Souza, Anthony E Mega, John Douglass, et al.
Blood Advances
|
September 22, 2021
Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma
Adam J Olszewski, Anna D Chorzalska, Max Petersen, et al.
British Journal of Haematology
|
November 10, 2022
Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles
Diana O Treaba, Dennis M Bonal, Anna Chorzalska, et al.
Breast Cancer Research and Treatment
|
June 4, 2021
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
M L Lopresti, J J Bian, B J Sakr, et al.
Blood
|
July 29, 2025
HiJAKing the Hematopoietic System: A Low-Frequency JAK2V617F Clone Drives Myeloproliferative Neoplasm Pathology
Dennis M Bonal, Alissa Oakes, Anna Chorzalska, et al.
Blood Advances
|
June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study
Narendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Nature Medicine
|
December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Lihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Journal of Hematology & Oncology
|
May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Blood
|
September 15, 2018
Bone marrow-specific loss of
Anna Chorzalska, John Morgan, Nagib Ahsan, et al.
Page
of 29